Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

e to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
                SVP & Chief Financial Officer
                Cadence Pharmaceuticals, Inc.
                858-436-1400

                          CADENCE PHARMACEUTICALS, INC.
                          (a development stage company)
                       CONDENSED STATEMENTS OF OPERATIONS
                                  (unaudited)

                                                  Three Months Ended
                                                        March 31,
                                                  2009            2008
    Operating expenses:
      Research and development                $6,139,342    $10,478,047
      Marketing                                  536,115        583,702
      General and administrative               2,811,747      2,667,038
      Other                                      650,786         28,257
        Total operating expenses              10,137,990     13,757,044

    Loss from operations                     (10,137,990)   (13,757,044)

    Other (expense) income, net                 (299,373)        40,129

    Net loss                                $(10,437,363)  $(13,716,915)

    Basic and diluted net loss per share(1)       $(0.24)        $(0.42)

    Shares used to compute basic and
    diluted net loss per share(1)             43,831,889     32,921,093

    (1) As a result of the issuance of 12,039,794 shares of common stock
        pursuant to a private placement in the first quarter of 2009 and
        9,240,307 shares of common stock pursuant to an effective shelf
        registration in the first qu
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
2. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 16, 2014 “Never say, ‘I ... Universität Marburg’s Department of Physics, advises young women ... newly released SPIE Women in Optics 18-month ... shy to ask questions.” , In the annual ... mathematics) occupations ranging from university professor and laboratory ...
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... Texas (PRWEB) December 17, 2014 ... on Global Quartz Tubing industry. For an overview ... definition, classification, application, industry chain structure, industry overview, ... quartz tubing industry has witnessed rapid ... a number of acquisitions. This report mentions quartz ...
(Date:12/17/2014)... Park, CA (PRWEB) December 17, 2014 ... announces today that it has entered into a ... Midland Company (ADM) to apply DNA2.0’s proprietary protein ... enzyme engineering process. , “We are extremely excited ... ProteinGPS engineering platform. This proprietary bioengineering technology ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... Definiens, the number one Health Image Intelligence™ company, and ... diagnostics, today announced a partnership to develop a unique ... will apply Definiens, image analysis technology to develop new ... a variety of cancer types. Cernostics is ...
... Inc., a subsidiary of Eisai Inc., announced today that it ... Care , a national support services organization for people affected ... programs for people facing lung and ovarian cancers.  The two ... families become aware of options available to help treat and ...
... 5, 2011) -- Using minute graphite particles 1000 times smaller ... Arizona State University hope to boost the efficiencyand profitabilityof solar ... more and more on rooftops, but they,re not necessarily the ... is that they can use only a fraction of the ...
Cached Biology Technology:Definiens and Cernostics Partner to Develop Multiplexed Cancer Diagnostic Tests 2Definiens and Cernostics Partner to Develop Multiplexed Cancer Diagnostic Tests 3Morphotek®, Inc. Receives Beacon Award From CancerCare 2Morphotek®, Inc. Receives Beacon Award From CancerCare 3Nanoparticles improve solar collection efficiency 2
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... (NSU) is using part of a $10 million block grant ... impact on the marine ecosystem, officials announced this week. ... in Florida selected to work on 27 research projects that ... marine life. The projects were selected by the Florida Institute ...
... to a biological invader that reaches its shores via ... Zebra mussels, Asian Longhorned Beetles, Kudzu, Triffid weed and ... destroying agriculture, harming human health and threatening biodiversity. ... and cost of controlling invaders against the economic necessity ...
... BOZEMAN, Mont. - More than 120 sturgeon and paddlefish ... 31 through Sept. 2 in Bozeman and at Chico ... annual meeting of the North American Chapter of the World ... study sturgeon and paddlefish in North America. The meeting ...
Cached Biology News:NSU scientists receive BP money to research oil spill's impact 2New analysis weighs lost trade, costs to control invasive species against economic damages 2New analysis weighs lost trade, costs to control invasive species against economic damages 3
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
albumin from bovine serum (BSA), 2,4-dinitrophenylated (DNP-BSA)...
Request Info...
albumin from bovine serum (BSA), Alexa Fluor® 647 conjugate...
Biology Products: